Hope for rare kidney disease: drug trial targets protein leak
NCT ID NCT06295770
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether obinutuzumab, a drug used for certain blood cancers, can help people with fibrillary glomerulonephritis (FGN), a rare kidney condition that causes protein leakage and can lead to kidney failure. Twenty adults with confirmed FGN will receive the drug intravenously twice in the first month and again at six months. Researchers will measure changes in protein levels in urine over a year to see if the drug improves kidney health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- obinutuzumab (Gazyva)
- What this could lead to
- If it works, this could point toward a treatment for fibrillary glomerulonephritis, a rare kidney disease, by reducing protein leakage and preserving kidney function.
- What could go wrong
- This is a small, early-phase trial with only 20 people, so results may not apply broadly. The drug may cause side effects like infections or infusion reactions, and it's not yet proven to be effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRILLARY GLOMERULONEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••